Johnson & Johnson got its start as a pioneer of sterile surgical sutures and continues to make advancements today. Jesse Nawrocki, Ph.D., shares how he and his award-winning team are working to make surgery easier for doctors and safer for patients.

Johnson & Johnson announced its plan to remain in New Brunswick, New Jersey, and to build a new world headquarters in the city. As part of this effort, the company formed a public-private partnership to revitalize the city, which has since transformed into a …

3 days ago · Johnson & Johnson Innovative Medicine is leading where medicine is going. Patients inform and inspire our science-based innovations, which continue to change and save lives.

Wherever you are in the world or your career, we want to get to know you! Sign up for our talent community and share your career goals—it’s the first place our recruiters look when they have …

NEW BRUNSWICK, NJ (March 8, 2022) – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company ...

Apr 24, 2013 · For more than 125 years, Johnson & Johnson has advanced the health and well-being of women, children and families around the world. We are reinvesting in our history by developing a cutting-edge virtual museum while also renovating the Johnson & Johnson Museum located on our campus in New Brunswick, New Jersey.

Apr 28, 2017 · Though no longer a source of the New Brunswick campus’ electricity, the Powerhouse is a reminder of the company’s early expansion, focus on the future and dedication to cutting-edge technology.

NEW BRUNSWICK, NJ (March 7, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash ...

NEW BRUNSWICK, NJ (January 8, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug ...

New Brunswick, NJ – April 1, 2019 – Johnson & Johnson (NYSE: JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash.